Streetbeat News

Analyst Ratings

PRG

Analysts have provided mixed ratings for PROG Holdings (NYSE:PRG) over the past three months, with a recent increase in the average 12-month price target to $48.8. The company's financial performance shows challenges in revenue growth and net margin, but strong ROE and ROA.

Portfolio Pulse from Benzinga Insights

September 10, 2024 | 2:01 pm

NBTB

Stephens & Co. analyst Matt Breese has reiterated an Equal-Weight rating on NBT Bancorp (NASDAQ:NBTB) and maintained a price target of $49.

Portfolio Pulse from Benzinga Newsdesk

September 10, 2024 | 2:01 pm

HAE

Haemonetics (NYSE:HAE) has been analyzed by four analysts, showing a range of ratings from bullish to indifferent. The average 12-month price target is $107.5, with a high of $125 and a low of $85. Recent analyst actions include a buy rating from BTIG, a neutral rating from Citigroup, and outperform ratings from JMP Securities and Barrington Research. Haemonetics has shown a revenue growth rate of 7.98% and strong financial metrics, including a net margin of 11.41% and a ROE of 4.11%.

Portfolio Pulse from Benzinga Insights

September 10, 2024 | 2:01 pm

HRMY

In the past three months, six analysts have rated Harmony Biosciences (NASDAQ:HRMY), with all ratings being bullish. The average 12-month price target remains at $52.0, with a high of $56.00 and a low of $48.00. Analysts from UBS, Needham, and Citigroup have maintained or announced 'Buy' ratings. Harmony Biosciences shows a positive revenue trend with a 28.76% growth rate, a net margin of 6.71%, and a conservative debt-to-equity ratio of 0.35.

Portfolio Pulse from Benzinga Insights

September 10, 2024 | 2:01 pm

DAVE

Analysts have evaluated Dave (NASDAQ:DAVE) over the past three months, with a mix of bullish and somewhat bullish ratings. The average 12-month price target is $60.57, a decrease from the previous $63.60. Dave has shown strong financial performance with notable revenue growth and efficient cost management, but its debt-to-equity ratio is higher than the industry average.

Portfolio Pulse from Benzinga Insights

September 10, 2024 | 2:01 pm

PAYO

Analysts have recently updated their ratings for Payoneer Global (NASDAQ:PAYO), with a majority being bullish. The average 12-month price target has increased to $8.75, reflecting a 12.9% rise. Payoneer has shown strong revenue growth but faces challenges in profitability and returns.

Portfolio Pulse from Benzinga Insights

September 10, 2024 | 2:00 pm

PRGS

Progress Software (NASDAQ:PRGS) has received mixed analyst ratings over the past three months, with a slight downward trend in average price targets. Analysts have maintained or adjusted their ratings based on market conditions, with a current average price target of $64.43. Despite a decline in revenue growth, Progress Software shows strong net margins and asset utilization but faces challenges with debt management and return on equity.

Portfolio Pulse from Benzinga Insights

September 10, 2024 | 2:00 pm

ZETA

DA Davidson analyst Clark Wright maintains a Buy rating on Zeta Global Holdings with a $30 price target.

Portfolio Pulse from Benzinga Newsdesk

September 10, 2024 | 1:59 pm

DLTR

Goldman Sachs analyst Kate McShane maintains a Buy rating on Dollar Tree (NASDAQ:DLTR) but lowers the price target from $145 to $90.

Portfolio Pulse from Benzinga Newsdesk

September 10, 2024 | 1:56 pm

PRGS

DA Davidson has reiterated its Buy rating for Progress Software (NASDAQ:PRGS) with a maintained price target of $65.

Portfolio Pulse from Benzinga Newsdesk

September 10, 2024 | 1:56 pm